During a conference call with investors, Biogen Inc. officials defended the price of Aduhelm (aducanumab) for Alzheimer’s disease (AD), with CEO Michel Vounatsos saying the $56,000 per year price tag was based on “the value it is expected to bring to patients, caregivers, and society.” Read More
DUBLIN – Aelis Farma SAS is banking $30 million up front as part of a strategic collaboration and option license deal with Indivior plc involving AEF-0117, its candidate drug for treating cannabis-related disorders, including addiction and psychosis. It could receive another $100 million, should Invidior trigger the option on completion of a phase IIb trial in the U.S. Read More
Dermavant Sciences Inc. has announced a $200 million financing deal to clear the way for a potential U.S. launch of its dermatology cream tapinarof, covering a potential milestone payment to Glaxosmithkline plc following a filing in severe psoriasis. Read More
Data presented to the American Society of Clinical Oncology and taken from Hookipa Pharma Inc.’s ongoing phase I/II study for treating advanced human papillomavirus 16-positive (HPV16+) cancers underwhelmed investors as the stock (NASDAQ:HOOK) sagged 19.25% on June 8. Read More
In a bid to bring more drug manufacturing back to the U.S. and to ensure an adequate supply of essential medicines, even in public health emergencies, the U.S. Department of Health and Human Services is forming a public-private consortium on advanced manufacturing and the onshoring of domestic production. Read More
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, and the role of ?-synuclein accumulation and the subsequent death of dopaminergic neurons in the midbrain have long been recognized as key steps in the disease. Progress in understanding genetic risk factors, meanwhile, has uncovered multiple genetic risk factors. Even though aging is the single biggest risk factor for PD, there are versions of the disorder that affect children. Read More
Holly Hand, a New York-based senior project manager overseeing a clinical trial for Neuralstem Inc. (now Seneca Biopharma Inc.), agreed to pay $103,875 to resolve an SEC complaint of insider trading. Read More
New hires and promotions in the biopharma industry, including: Brooklyn, Flavocure, Fusion, Carisma, Celsion, Design, Hawaii, Ironwood, Mirum, Morphimmune, Ocuphire, Pyxis, Umoja, Viacyte. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbive, Alessa, Amicus, Amryt, Ascletis, Bavarian Nordic, Bergenbio, Bluebird, Cantargia, Crestone, Cullinan, Iaso, Incyte, Kiniksa, Liminal, Moderna, Neoimmunetech, Novo Nordisk, Spinogenix Takeda, VBI. Read More
